Intensity Therapeutics Inc. (NASDAQ:INTS) Receives Average Rating of “Moderate Buy” from Analysts

Intensity Therapeutics Inc. (NASDAQ:INTS) has earned an average rating of “Moderate Buy” from the four analysts that are covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, two have given a buy rating and one has issued a strong buy rating on the company. The average 12-month target price among brokerages that have updated their coverage on the stock in the last year is $37.50.

A number of analysts have recently weighed in on the company. Wall Street Zen raised Intensity Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, April 4th. Weiss Ratings cut Intensity Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday, April 24th. Finally, Freedom Capital raised Intensity Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Monday, March 30th.

Intensity Therapeutics Trading Down 0.4%

Shares of NASDAQ:INTS opened at $5.09 on Friday. Intensity Therapeutics has a 12-month low of $4.63 and a 12-month high of $43.50. The business’s fifty day simple moving average is $6.11 and its 200-day simple moving average is $8.71. The company has a market capitalization of $13.49 million, a PE ratio of -0.50 and a beta of 2.94. The company has a current ratio of 5.92, a quick ratio of 5.92 and a debt-to-equity ratio of 0.01.

Intensity Therapeutics (NASDAQ:INTS) last announced its quarterly earnings results on Thursday, May 7th. The company reported ($0.96) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.08) by $0.12. As a group, equities research analysts predict that Intensity Therapeutics will post -3.46 earnings per share for the current fiscal year.

Institutional Trading of Intensity Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in INTS. Jane Street Group LLC acquired a new stake in Intensity Therapeutics during the 4th quarter worth about $26,000. Corient Private Wealth LLC acquired a new stake in Intensity Therapeutics during the 4th quarter worth about $41,000. Mesirow Financial Investment Management Inc. lifted its position in Intensity Therapeutics by 81.8% during the 3rd quarter. Mesirow Financial Investment Management Inc. now owns 200,000 shares of the company’s stock worth $49,000 after acquiring an additional 90,000 shares during the period. State Street Corp lifted its position in Intensity Therapeutics by 839.3% during the 4th quarter. State Street Corp now owns 136,200 shares of the company’s stock worth $56,000 after acquiring an additional 121,700 shares during the period. Finally, Legacy Advisors LLC acquired a new position in shares of Intensity Therapeutics in the 4th quarter valued at about $63,000. Institutional investors and hedge funds own 3.74% of the company’s stock.

About Intensity Therapeutics

Intensity Therapeutics, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of cancer drugs to treat solid tumors. The company's lead product candidate is INT230-6, which is in Phase 2 clinical trial for the treatment of refractory solid tumors; and pancreatic, colon, bile duct, squamous cell carcinoma, sarcoma, breast, and liver cancers. It has a collaboration agreement with Merck Sharpe & Dohme Corp. to evaluate the combination of INT230-6 and Keytruda in patients with advanced pancreatic, colon, squamous cell, and bile duct malignancies; Bristol-Myers Squibb Company to evaluate the combination of INT230-6 with Yervoy in patients with advanced liver, breast, and sarcoma cancers; and Ottawa Hospital Research Institute and the Ontario Institute of Cancer Research to study INT230-6 in a randomized controlled neoadjuvant phase II study in women with early-stage breast cancer.